1
|
Carron CP, Trujillo JI, Olson KL, Huang W, Hamper BC, Dice T, Neal BE, Pelc MJ, Day JE, Rohrer DC, Kiefer JR, Moon JB, Schweitzer BA, Blake TD, Turner SR, Woerndle R, Case BL, Bono CP, Dilworth VM, Funckes-Shippy CL, Hood BL, Jerome GM, Kornmeier CM, Radabaugh MR, Williams ML, Davies MS, Wegner CD, Welsch DJ, Abraham WM, Warren CJ, Dowty ME, Hua F, Zutshi A, Yang JZ, Thorarensen A. Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS). ACS Med Chem Lett 2010; 1:59-63. [PMID: 24900177 DOI: 10.1021/ml900025z] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2009] [Accepted: 01/22/2010] [Indexed: 11/29/2022] Open
Abstract
Hematopoietic prostaglandin D synthase (HPGDS) is primarly expressed in mast cells, antigen-presenting cells, and Th-2 cells. HPGDS converts PGH2 into PGD2, a mediator thought to play a pivotal role in airway allergy and inflammatory processes. In this letter, we report the discovery of an orally potent and selective inhibitor of HPGDS that reduces the antigen-induced response in allergic sheep.
Collapse
Affiliation(s)
- Chris P. Carron
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - John I. Trujillo
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Kirk L. Olson
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Wei Huang
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Bruce C. Hamper
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Tom Dice
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Bradley E. Neal
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Matthew J. Pelc
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Jacqueline E. Day
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Douglas C. Rohrer
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - James R. Kiefer
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Joseph B. Moon
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Barbara A. Schweitzer
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Tanisha D. Blake
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Steve R. Turner
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Rhonda Woerndle
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Brenda L. Case
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Christine P. Bono
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Vickie M. Dilworth
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | | | - Becky L. Hood
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Gina M. Jerome
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Christine M. Kornmeier
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Melissa R. Radabaugh
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Melanie L. Williams
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Michael S. Davies
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Craig D. Wegner
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Dean J. Welsch
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - William M. Abraham
- Department of Research, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, Florida 33140
| | - Chad J. Warren
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Martin E. Dowty
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Fengmei Hua
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Anup Zutshi
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Jerry Z. Yang
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| | - Atli Thorarensen
- Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017
| |
Collapse
|
2
|
Walker JK, Selness SR, Devraj RV, Hepperle ME, Naing W, Shieh H, Kurambail R, Yang S, Flynn DL, Benson AG, Messing DM, Dice T, Kim T, Lindmark RJ, Monahan JB, Portanova J. Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase. Bioorg Med Chem Lett 2010; 20:2634-8. [PMID: 20227876 DOI: 10.1016/j.bmcl.2010.02.047] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2010] [Revised: 02/10/2010] [Accepted: 02/10/2010] [Indexed: 10/19/2022]
Abstract
Starting from an initial HTS screening lead, a novel series of C(5)-substituted diaryl pyrazoles were developed that showed potent inhibition of p38alpha kinase. Key to this outcome was the switch from a pyridyl to pyrimidine at the C(4)-position leading to analogs that were potent in human whole blood based cell assay as well as in a number of animal efficacy models for rheumatoid arthritis. Ultimately, we identified a clinical candidate from this substrate; SD-0006.
Collapse
Affiliation(s)
- John K Walker
- Pfizer Global Research and Development, St. Louis, MO 63017, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|